Dexcom management check
DXCM · Health Care · Health Care Equipment · CEO Jacob Steven Leach
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
3943rdDetail
$100 invested at the start of fiscal 2021 grew to $72, against $79 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8555thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.70 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.9% of net income
What does the CEO cost owners?
$16.3m pay · $836.3m net income, FY2025
2629thDetail
$16.3m of reported pay in fiscal 2025, against $836.3m of net income.
- WatchCEO stake ≈ 2.0 years of pay
Do they own the stock?
417,457 shares ≈ $33.2m
6 mo: ▲ $0 bought · ▼ $12.2m sold
5056thDetail
The CEO holds 417,457 shares, directly or through trusts (unvested awards not counted): about 2.0 years of pay. Light activity: no buys, $12.2m sold in six months. 25 of 25 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.4% a year; flagged above +2%
Stock pay 3.4% of revenue
8072ndDetail
Diluted shares changed -2.4% a year over the last three fiscal years. Stock-based pay was 3.4% of revenue in the latest year.
- Watch13 leadership filings in 3 years
Is leadership stable?
13 filings under 8-K 5.02 in 3 years
6038thDetail
13 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- FlagRed flags on file
Are the books clean?
Since 2021
- 0Restated
- 1Auditor changes
- 0Late filings
- 010-K amended
307thDetail
1 auditor change (8-K 4.01) since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 15, 2026.
Other key measures2025 Adjusted RevenueNon-GAAP Operating MarginRelative Total Shareholder Return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | — | $16.3m | $13.0m | $6.6m | $72 | $79 | $836.3m |
| 2024 | — | $15.8m | −$8.7m | $5.6m | $84 | $79 | $576.2m |
| 2023 | — | $15.7m | $23.0m | $5.0m | $134 | $75 | $541.5m |
| 2022 | — | $15.4m | $5.7m | $4.4m | $123 | $79 | $341.2m |
| 2021 | — | $12.0m | $36.1m | $5.0m | $145 | $104 | $216.9m |
Insiders and the CEO's stakeQuiet
- President, CEO, and Director
- Jacob Steven Leach
- Shares held
- 417,457
- At that filing's price
- ≈ $33.2m
- Latest Form 4
- Nov 8, 2026
Light activity: no buys, $12.2m sold in six months. 25 of 25 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldKevin R SayerExecutive Chair · 10b5-1 plan$8.3mAug 20, 2026
- SoldMichael Jon BrownEVP Chief Legal Compliance Off · 10b5-1 plan$841kNov 16, 2026
- SoldJon ColemanEVP, Chief Commercial Officer · 10b5-1 plan$723kJun 4, 2026
- SoldNicholas AugustinosDirector · 10b5-1 plan$680kSep 15, 2026
Leadership and governance on file
All 19 filings
- Sep 14, 2026Leadership change8-K 5.02
- Sep 10, 2026Leadership change8-K 5.02
- Mar 2, 2026Leadership change8-K 5.02
- Feb 26, 2026Leadership change8-K 5.02
- Dec 22, 2025Leadership change8-K 5.02
- Oct 27, 2025Leadership change8-K 5.02
- Sep 16, 2025Leadership change8-K 5.02
- Jul 30, 2025Leadership change8-K 5.02
- May 13, 2025Leadership change8-K 5.02
- May 9, 2025Leadership change8-K/A 5.02
- May 9, 2025Leadership change8-K 5.02
- May 2, 2025Leadership change8-K 5.02
- Mar 25, 2025Auditor change8-K 4.01
- Mar 10, 2025Leadership change8-K 5.02
- Aug 28, 2023Leadership change8-K 5.02
- May 19, 2023Leadership change8-K 5.02
- Aug 31, 2022Leadership change8-K 5.02
- Jul 8, 2022Leadership change8-K 5.02
- Dec 17, 2021Leadership change8-K 5.02
Latest shareholder vote results: May 28, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $2.5bn returned to owners in buybacks and dividends, 99% of net income, and $720.7m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.4bn | $2.9bn | $3.6bn | $4.0bn | $4.7bn |
| Net income | $216.9m | $341.2m | $541.5m | $576.2m | $836.3m |
| Stock-based pay | $113.4m | $126.5m | $150.8m | $170.4m | $159.6m |
| Buybacks | $0 | $557.7m | $688.7m | $750.0m | $500.0m |
| Dividends | — | — | — | — | — |
| Diluted shares | 429m | 428m | 426m | 413m | 406m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.